MTF1 and myelodysplastic syndrome: A clinical trial testing LOR-253 in patients with AML and myelodysplastic syndrome is currently ongoing (ClinicalTrials.gov: NCT02267863). Our results suggest that the potential role of MTF1 in gynecologic and basal breast cancers merits further investigation.